Connect Biopharma Holdings Ltd - ADR
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
(0.0% 1d) (3.0% 1m) (32.2% 1y) (0.0% 2d) (-1.4% 3d) (-11.0% 7d) (-44.08% volume)
Earnings Calendar:
Market Cap: $ 76,549,467
https://www.connectbiopharm.com
Sec Filling | Patents | 2021 employees
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from its T cell-driven research. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Its second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).
ceiling treatment brands antibody t-cell
add to watch list Paper trade email alert is off
Press-releases
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
business year update biopharma financial results
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
Published: 2024-03-19 (Crawled : 13:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: 2.42%
H: 0.0%
C: -5.51%
conference disease biopharma
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
Published: 2024-02-12 (Crawled : 22:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: -1.18%
H: 5.56%
C: -2.78%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: 0.0%
biopharma
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
Published: 2023-12-12 (Crawled : 11:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: -8.59%
H: 5.75%
C: -0.57%
positive biopharma global topline results
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
Published: 2023-12-11 (Crawled : 21:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: -8.59%
H: 5.75%
C: -0.57%
biopharma global trial
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
Published: 2023-11-21 (Crawled : 11:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: 6.31%
H: 2.28%
C: -42.47%
biopharma collaboration agreement china
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
Published: 2023-11-21 (Crawled : 11:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: 6.31%
H: 2.28%
C: -42.47%
dermatitis positive biopharma trial china
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
Published: 2023-11-20 (Crawled : 22:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: 6.31%
H: 2.28%
C: -42.47%
dermatitis biopharma trial china
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
Published: 2023-09-12 (Crawled : 20:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: -1.02%
H: 4.0%
C: 3.99%
business update biopharma financial results
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
Published: 2023-09-12 (Crawled : 10:00) - globenewswire.com
CNTB | $1.39 3.57% 41K
|
Professional, Scientific, and T...
|
| O: -1.41%
H: 0.0%
C: -1.43%
nasdaq biopharma
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10